Cargando…

Clinical utility of androgen receptor gene aberrations in circulating cell-free DNA as a biomarker for treatment of castration-resistant prostate cancer

The therapeutic landscape of castration-resistant prostate cancer (CRPC) has rapidly expanded. There is a need to develop noninvasive biomarkers to guide treatment. We established a highly sensitive method for analyzing androgen receptor gene (AR) copy numbers (CN) and mutations in plasma circulatin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sumiyoshi, Takayuki, Mizuno, Kei, Yamasaki, Toshinari, Miyazaki, Yu, Makino, Yuki, Okasho, Kosuke, Li, Xin, Utsunomiya, Noriaki, Goto, Takayuki, Kobayashi, Takashi, Terada, Naoki, Inoue, Takahiro, Kamba, Tomomi, Fujimoto, Akihiro, Ogawa, Osamu, Akamatsu, Shusuke
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411952/ https://www.ncbi.nlm.nih.gov/pubmed/30858508 http://dx.doi.org/10.1038/s41598-019-40719-y

Ejemplares similares

Castration-Resistant Prostate Cancer Refractory to Second-Generation Androgen Receptor Axis-Targeted Agents: Opportunities and Challenges
por: Kita, Yuki, et al.
Publicado: (2018)

Detection of von Hippel‐Lindau gene mutation in circulating cell‐free DNA for clear cell renal cell carcinoma
por: Sumiyoshi, Takayuki, et al.
Publicado: (2021)

Functional and genomic characterization of patient‐derived xenograft model to study the adaptation to mTORC1 inhibitor in clear cell renal cell carcinoma
por: Sakamoto, Hiromasa, et al.
Publicado: (2020)

Consecutive Prostate Cancer Specimens Revealed Increased Aldo–Keto Reductase Family 1 Member C3 Expression with Progression to Castration-Resistant Prostate Cancer
por: Miyazaki, Yu, et al.
Publicado: (2019)

Up‐regulation of secretory leukocyte protease inhibitor in human samples might have a potential role of predicting prostate cancer recurrence and progression after surgery and hormonal therapy
por: Miyazaki, Yu, et al.
Publicado: (2022)

Extracellular vesicles secreted from bone metastatic renal cell carcinoma promote angiogenesis and endothelial gap formation in bone marrow in a time-dependent manner in a preclinical mouse model
por: Takeda, Masashi, et al.
Publicado: (2023)

Solitary recurrence of prostate cancer surrounded by seminal vesicle/vas deferens‐like epithelium
por: Takamori, Hajime, et al.
Publicado: (2020)

Comprehensive genomics in androgen receptor-dependent castration-resistant prostate cancer identifies an adaptation pathway mediated by opioid receptor kappa 1
por: Makino, Yuki, et al.
Publicado: (2022)

CCL2 as a potential therapeutic target for clear cell renal cell carcinoma
por: Arakaki, Ryuichiro, et al.
Publicado: (2016)

Narrative review of challenges in the management of advanced neuroendocrine prostate cancer
por: Okasho, Kosuke, et al.
Publicado: (2021)

Author Correction: Comprehensive genomics in androgen receptor-dependent castration-resistant prostate cancer identifies an adaptation pathway mediated by opioid receptor kappa 1
por: Makino, Yuki, et al.
Publicado: (2022)

Experimental Evidence of Persistent Androgen-Receptor-Dependency in Castration-Resistant Prostate Cancer
por: Kobayashi, Takashi, et al.
Publicado: (2013)

Establishment and characterization of a novel treatment‐related neuroendocrine prostate cancer cell line KUCaP13
por: Okasho, Kosuke, et al.
Publicado: (2021)

A case of microsatellite instability-high clinically advanced castration-resistant prostate cancer showing a remarkable response to pembrolizumab sustained over at least 18 months
por: Shimizu, Kosuke, et al.
Publicado: (2022)

Rapidly Progressive Bladder Cancer Diagnosed because of Spontaneous Bladder Rupture
por: Hagimoto, Hiroki, et al.
Publicado: (2022)

Association of Missense Polymorphism in HSD3B1 With Outcomes Among Men With Prostate Cancer Treated With Androgen-Deprivation Therapy or Abiraterone
por: Shiota, Masaki, et al.
Publicado: (2019)

Identification of the α2 chain of interleukin‐13 receptor as a potential biomarker for predicting castration resistance of prostate cancer using patient‐derived xenograft models
por: Nagai, Takahiro, et al.
Publicado: (2022)

Role of IL13RA2 in Sunitinib Resistance in Clear Cell Renal Cell Carcinoma
por: Shibasaki, Noboru, et al.
Publicado: (2015)

The Expression Profile of Phosphatidylinositol in High Spatial Resolution Imaging Mass Spectrometry as a Potential Biomarker for Prostate Cancer
por: Goto, Takayuki, et al.
Publicado: (2014)

Ten‐year outcomes of whole‐pelvic intensity‐modulated radiation therapy for prostate cancer with regional lymph node metastasis
por: Nakamura, Kiyonao, et al.
Publicado: (2022)

Ten-year outcomes of high-dose intensity-modulated radiation therapy for nonmetastatic prostate cancer with unfavorable risk: early initiation of salvage therapy may replace long-term adjuvant androgen deprivation
por: Aizawa, Rihito, et al.
Publicado: (2019)

Case Report: A Case of Renal Cell Carcinoma Unclassified With Medullary Phenotype Exhibiting a Favorable Response to Combined Immune Checkpoint Blockade
por: Takeda, Masashi, et al.
Publicado: (2022)

Data processing on a comparative evaluation of the extraction and analysis procedures for urinary phospholipid and lysophospholipid using MALDI-TOF/MS
por: Li, Xin, et al.
Publicado: (2019)

The Roles of Extracellular Vesicles in the Progression of Renal Cell Carcinoma and Their Potential for Future Clinical Application
por: Takeda, Masashi, et al.
Publicado: (2023)

Genetic variations predicting progression with docetaxel and novel androgen‐receptor pathway inhibitors
por: Shiota, Masaki, et al.
Publicado: (2023)

A narrative review of urinary phospholipids: from biochemical aspect towards clinical application
por: Li, Xin, et al.
Publicado: (2021)

A 45,X/46,XY Male with Orchidopexy Diagnosed with Mixed Germ Cell Tumor After 21-year Follow-up
por: Kubota, Masashi, et al.
Publicado: (2017)

eVIDENCE: a practical variant filtering for low-frequency variants detection in cell-free DNA
por: Mizuno, Kei, et al.
Publicado: (2019)

Gene amplification of YB‐1 in castration‐resistant prostate cancer in association with aberrant androgen receptor expression
por: Shiota, Masaki, et al.
Publicado: (2020)

Robot-assisted partial nephrectomy for renal cell carcinoma in the isthmus of horseshoe kidney
por: Sawada, Atsuro, et al.
Publicado: (2022)

Long-term clinical outcomes of salvage pelvic radiation therapy for oligo-recurrent pelvic lymph nodes after definitive external-beam radiation therapy for non-metastatic prostate cancer
por: Sato, Genki Edward, et al.
Publicado: (2020)

Paraurachal paraganglioma
por: Tsuruta, Masafumi, et al.
Publicado: (2022)

Arteriovenous fistula after robot‐assisted laparoscopic prostatectomy: A rare case report
por: Suzuki, Ryosuke, et al.
Publicado: (2019)

Androgens as therapy for androgen receptor-positive castration-resistant prostate cancer
por: Chuu, Chih-Pin, et al.
Publicado: (2011)

Structural chromosome aberrations cause swelling of the nucleus
por: Takeshita, Kenji, et al.
Publicado: (2016)

IFN-Gamma Expression in the Tumor Microenvironment and CD8-Positive Tumor-Infiltrating Lymphocytes as Prognostic Markers in Urothelial Cancer Patients Receiving Pembrolizumab
por: Sakatani, Toru, et al.
Publicado: (2022)

Genetic Polymorphisms and Pharmacotherapy for Prostate Cancer
por: Shiota, Masaki, et al.
Publicado: (2021)

Incomplete sagittal septum of the bladder with cystolithiasis
por: Fujimoto, Takeru, et al.
Publicado: (2022)

Clinical significance of IDC‐P as predictive factor after intensity‐modulated radiation therapy
por: Aizawa, Rihito, et al.
Publicado: (2022)

Antitumor effect of WEE1 blockade as monotherapy or in combination with cisplatin in urothelial cancer
por: Murakami, Kaoru, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_nlss2k8lk8889fs0ftquv11glm